Caribou Biosciences
A clinical-stage CRISPR genome-editing biopharmaceutical company.
The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve antitumor activity.
Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T and CAR-NK platforms as readily available treatments for patients with hematologic malignancies and solid tumors.
Latest Caribou Biosciences News & Features
8 January 2024
27 September 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze